Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- About
ZYXI 
Zynex Inc (ZYXI)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/11/2025: ZYXI (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
3 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $3.7
1 Year Target Price $3.7
| 0 | Strong Buy |
| 1 | Buy |
| 2 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -43.02% | Avg. Invested days 21 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 12/11/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 26.21M USD | Price to earnings Ratio - | 1Y Target Price 3.7 |
Price to earnings Ratio - | 1Y Target Price 3.7 | ||
Volume (30-day avg) 3 | Beta 1 | 52 Weeks Range 0.38 - 8.72 | Updated Date 12/11/2025 |
52 Weeks Range 0.38 - 8.72 | Updated Date 12/11/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.41 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -68.35% | Operating Margin (TTM) -98.97% |
Management Effectiveness
Return on Assets (TTM) -27.11% | Return on Equity (TTM) -168.22% |
Valuation
Trailing PE - | Forward PE 16.61 | Enterprise Value 85000716 | Price to Sales(TTM) 0.24 |
Enterprise Value 85000716 | Price to Sales(TTM) 0.24 | ||
Enterprise Value to Revenue 0.79 | Enterprise Value to EBITDA 20.66 | Shares Outstanding 30388635 | Shares Floating 15791758 |
Shares Outstanding 30388635 | Shares Floating 15791758 | ||
Percent Insiders 48.16 | Percent Institutions 13.7 |
Upturn AI SWOT
Zynex Inc
Company Overview
History and Background
Zynex Inc. was founded in 1997 and is a leading provider of advanced healthcare solutions. The company has evolved significantly, focusing on developing, manufacturing, and marketing medical devices, particularly in the areas of pain management and rehabilitation.
Core Business Areas
- Medical Devices: Designs, manufactures, and markets advanced medical devices for pain management, rehabilitation, and neurostimulation.
- Home Health Services: Provides home health monitoring and telehealth services to patients, supplementing their in-home care.
Leadership and Structure
Zynex Inc. is led by its Founder and CEO, Patrick L. Williams. The company operates with a functional organizational structure, with departments focused on research and development, manufacturing, sales and marketing, and clinical support.
Top Products and Market Share
Key Offerings
- NexWave: A non-narcotic pain relief device utilizing electrotherapy. It is a flagship product in Zynex's pain management portfolio. Competitors include companies like DJO Global (Empi) and Medtronic in the broader electrotherapy market.
- CM-100: A physical therapy device for muscle re-education and strengthening, commonly used in rehabilitation settings. Competitors include manufacturers of electrical stimulation devices for physical therapy.
- NeuroWave: A neuro-stimulator for advanced pain management and neurological conditions. Competitors are typically other medical device manufacturers offering neuro-modulation solutions.
Market Dynamics
Industry Overview
The medical device industry, particularly in pain management and rehabilitation, is characterized by increasing demand for non-invasive and non-narcotic treatment options. Technological advancements and an aging global population are key drivers. The market is competitive with both established players and innovative startups.
Positioning
Zynex Inc. positions itself as a provider of innovative, high-quality medical devices that offer significant patient benefits and cost-effectiveness. Its focus on direct-to-consumer sales channels and integrated home health services provides a competitive edge.
Total Addressable Market (TAM)
The global pain management market is valued in the tens of billions of dollars and is projected to grow significantly. The rehabilitation device market also represents a substantial opportunity. Zynex Inc. is positioned to capture a niche within these broad markets through its specialized product offerings and direct sales model.
Upturn SWOT Analysis
Strengths
- Proprietary technologies in pain management and neurostimulation.
- Strong direct-to-consumer sales and marketing model.
- Growing revenue and improving profitability.
- Focus on non-narcotic pain relief solutions.
- Experienced management team.
Weaknesses
- Reliance on a limited number of key products.
- Potential for increased competition.
- Ongoing research and development costs.
- Regulatory hurdles in the medical device industry.
Opportunities
- Expansion into new geographic markets.
- Development of new product lines and technologies.
- Increased demand for telehealth and remote patient monitoring.
- Partnerships with healthcare providers and distributors.
- Growing awareness and acceptance of electrotherapy and neurostimulation.
Threats
- Intensifying competition from larger medical device companies.
- Changes in healthcare reimbursement policies.
- Potential for adverse regulatory changes.
- Economic downturns affecting healthcare spending.
- Technological obsolescence.
Competitors and Market Share
Key Competitors
- DJ O Global (EMPI)
- Medtronic
- Abbott Laboratories
- Boston Scientific
Competitive Landscape
Zynex Inc. differentiates itself through its specialized focus on electrotherapy for pain management and rehabilitation, its direct-to-consumer model, and its integrated telehealth services. Larger competitors have broader product portfolios and established distribution networks, but Zynex's agility and targeted approach are key advantages.
Growth Trajectory and Initiatives
Historical Growth: Zynex Inc. has demonstrated a consistent historical growth trajectory, driven by increasing sales of its core medical devices and expansion of its service offerings.
Future Projections: Future growth is projected to be supported by continued innovation, market penetration, and potential new product launches. Analyst estimates would provide specific forward-looking figures.
Recent Initiatives: Recent initiatives include expansion of its sales force, development of new product features, and enhancements to its telehealth platform.
Summary
Zynex Inc. is a growing medical device company with a strong focus on non-narcotic pain management and rehabilitation. Its direct-to-consumer sales model and innovative product pipeline are key strengths. The company needs to vigilantly monitor competition and adapt to evolving healthcare regulations to sustain its growth trajectory.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Zynex Inc. Investor Relations
- Financial News Outlets (e.g., Bloomberg, Reuters)
- Market Research Reports (General Industry Data)
Disclaimers:
This analysis is based on publicly available information and is for informational purposes only. It does not constitute financial advice. Investors should conduct their own due diligence before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Zynex Inc
Exchange NASDAQ | Headquaters Englewood, CO, United States | ||
IPO Launch date 2002-12-31 | CEO & Director Dr. Steven Lewis Dyson Ph.D. | ||
Sector Healthcare | Industry Medical Distribution | Full time employees 1000 | Website https://www.zynex.com |
Full time employees 1000 | Website https://www.zynex.com | ||
Zynex, Inc., together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain, and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography and electric stimulation technology device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; E-Wave, an NMES device; and M-Wave, an NMES device. It also supplies private labeled products, including electrodes for the delivery of electrical current to the body; and batteries for use in electrotherapy products. In addition, the company distributes Comfortrac/Saunders for cervical traction, JetStream for hot/cold therapy, LSO Back Braces for lumbar support, braces for rehabilitation support for knee and wrist, and Dynacomp for cold compression therapy. Further, it develops Zynex Fluid Monitoring System (CM-1500); Zynex Wireless Fluid Monitoring System (CM-1600), a noninvasive monitoring device designed to measure relative changes in fluid volume in adult patients; NiCO CO-Oximeter, a laser photoplethysmographic patient monitoring device; and HemeOx tHb Oximeter, a laser-based total hemoglobin pulse oximeter. The company provides its products for use in pain management and control; stroke and spinal cord injury rehabilitation; and fluid monitoring and pulse oximetry monitoring. It sells its products through direct sales force primarily in the United States. Zynex, Inc. was founded in 1996 and is headquartered in Englewood, Colorado.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.